On Jan. 31, the CDC's chief science officer sent an internal email that informed the agency’s division heads that all papers ...

Gastrointestinal-focused CRO Alimentiv is upgrading its clinical trials with software firm PhaseV’s adaptive trial technology ...

Baxter President and CEO José Almeida has announced his retirement, effective immediately, after nearly a decade of leading ...

Sionna Therapeutics is eyeing a $156 million IPO as the cystic-fibrosis-focused biotech looks to take its lead candidate into ...

AdvanCell has secured $112 million in a Sanofi Ventures-backed series C funding round as the Australian radiopharma company ...

Acelyrin has punted the autoimmune drug prospect izokibep back to Affibody, complet | Acelyrin has punted the autoimmune drug prospect izokibep back to Affibody, completing a retreat from its former ...

The inhaled mebufotenin candidate, dubbed GH001, was evaluated in the midstage study of 81 patients with treatment-resistant depression. The 40 patients who received GH001 saw an average 15.2 point ...

President Donald Trump said his administration will install 25% tariffs on goods from Canada and Mexico, ending the largely ...

After spending years developing its endoscopic device treatment for patients with Type 2 diabetes, Fractyl Health is now ...

Cullinan Therapeutics has announced that its lead asset has aced a midstage lung cancer trial—but the biotech is keeping the ...

After parting ways with BeiGene in 2023, Novartis effectively bowed out of the PD-1 race. | The rising class of bispecifics ...

After leading Japan’s largest drugmaker for 11 years, Takeda CEO Christophe Weber plans to step down in June of 2026. He will ...